Portal de Periódicos da CAPES

Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases

2006; Elsevier BV; Volume: 56; Issue: 1 Linguagem: Inglês

10.1016/j.jaad.2006.05.068

1097-6787

Hope Dinh, Christopher McCormack, Stephen Hall, H. Miles Prince,

Immunodeficiency and Autoimmune Disorders

Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis. Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis.